What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice?

1 day ago 1

Unlock banal picks and a broker-level newsfeed that powers Wall Street.

Soumya Eswaran

Wed, Apr 2, 2025, 5:19 AM 3 min read

Renaissance Investment Management, an concern absorption company, released its Q4 2024 “Small Cap Growth Strategy” capitalist letter. A transcript of the missive tin beryllium downloaded here. The Russell 2000 Growth Index generated a instrumentality of 1.7% successful the 4th quarter, bringing the yearly returns to 15.2%. The portfolio generated affirmative returns successful the 4th fourth and outperformed the Index. The outperformance was driven by banal enactment successful Information Technology and underweight presumption and banal enactment successful Health Care, portion banal enactment successful Communication Services and Consumer Discretionary detracted. For much accusation connected the fund’s champion picks successful 2024, delight cheque its apical 5 holdings.

In its 4th fourth 2024 capitalist letter, Renaissance Investment Management Small Cap Growth Strategy emphasized stocks specified arsenic Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is simply a commercial-stage biopharmaceutical company. The one-month instrumentality Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was 9.27%, and its shares gained 54.42% of their worth implicit the past 52 weeks. On April 1, 2025, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) banal closed astatine $23.92 per stock with a marketplace capitalization of $2.905 billion.

Renaissance Investment Management Small Cap Growth Strategy stated the pursuing regarding Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) successful its Q4 2024 capitalist letter:

"Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), a biopharma institution focused connected neurological and neuromuscular disorders, was a caller presumption added during the quarter. The institution has 3 commercialized drugs successful the uncommon orphan conception that absorption connected the cardinal tense system. The institution launched a caller cause successful 2024 and has seen income ramp supra expectations. Catalyst is besides looking to get further drugs successful uncommon illness classifications to heighten institution growth. We judge that the company’s strategy to people the orphan cause marketplace could make semipermanent maturation opportunities with precocious barriers to introduction that should let the institution to thrust dependable maturation going forward."

A idiosyncratic successful a laboratory researching a neurological disease.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge money portfolios held Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) astatine the extremity of the 4th fourth compared to 32 successful the 3rd quarter. In the 2024, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) reported $491.7 cardinal successful revenues, representing a 23.5% summation from 2023. While we admit the imaginable of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) arsenic an investment, our condemnation lies successful the content that AI stocks clasp greater committedness for delivering higher returns, and doing truthful wrong a shorter timeframe. If you are looking for an AI banal that is arsenic promising arsenic NVIDIA but that trades astatine little than 5 times its earnings, cheque retired our study astir the cheapest AI stock.